OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, Richard B. Lock, Zhaohui Gu et al.|Clinical Cancer Research|2019Cited by 53
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancerChelsea Mayoh, Paul G. Ekert|Genome Medicine|2023Cited by 10
24 (PB012): Runx1t1 is an epigenetic regulator essential for MYCN-driven neuroblastoma tumorigenesisMurray D. Norris, Michelle Haber, Jayne Murray et al.|European Journal of Cancer|2024Cited by 0